Carrigent

Carrigent is a clinical-stage biotechnology company specializing in the development of multivalent therapeutics designed to enhance binding affinity and specificity for biological targets. The company's proprietary platform utilizes a scaffold to display multiple ligands, effectively mimicking natural biological interactions to treat infectious diseases and cancer. Its lead candidate, CRG-2501, is a multivalent inhibitor developed to prevent and treat COVID-19 by blocking viral entry at the mucosal surface. Carrigent aims to leverage its technology to address targets that are difficult to hit with traditional monovalent drugs, such as rapidly mutating viruses. The company was spun out of the University of Michigan and is led by experts in nanotechnology and immunology.